EMA Authorised: Conexxence (denosumab) — Fresenius Kabi Deutschland GmbH

View source ↗

Summary

EMA authorised Conexxence (denosumab) for osteoporosis indications, including postmenopausal osteoporosis and bone resorption conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Resorption Disorders
• Osteoporosis
• Osteoporosis Postmenopausal

Drugs mentioned

• CONEXXENCE (DENOSUMAB)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis;Osteoporosis, Postmenopausal;Bone Resorption. MAH: Fresenius Kabi Deutschland GmbH. Decision date: 13/08/2026